THERAPEUTICALLY EFFECTIVE COMBINATION OF A FLT3 INHIBITOR AND A BCL-2 INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Dec 26, 2024
app pub date -
Oct 20, 2022
filing date -
Oct 20, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
This invention relates to pharmaceutical compositions, pharmaceutical combinations and methods for the treatment of acute myeloid leukemia by combined use of a therapeutically effective combination of a compound of Chemical Formula 1, or a pharmaceutically acceptable salt thereof, solvate thereof, stereoisomer thereof, tautomer thereof, or combination thereof, wherein Ea, Eb, Ec, Ed, Z′, X′, Q, and k are defined herein; and a Bcl-2 inhibitor, or a Bcl-2 inhibitor and a hypomethylating agent.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully